Market Closed -
Euronext Bruxelles
11:35:22 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
358.6
EUR
|
-1.24%
|
|
+2.66%
|
+4.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,141
|
11,400
|
16,291
|
19,269
|
20,293
|
21,296
|
-
|
-
|
Enterprise Value (EV)
1 |
4,811
|
9,781
|
14,186
|
18,515
|
20,293
|
18,990
|
18,824
|
18,341
|
P/E ratio
|
-34
x
|
-20.8
x
|
-43.8
x
|
-28.3
x
|
-72.1
x
|
-145
x
|
108
x
|
36.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
74.4
x
|
209
x
|
33.5
x
|
45.9
x
|
17.3
x
|
12.7
x
|
9.3
x
|
7.08
x
|
EV / Revenue
|
58.3
x
|
179
x
|
29.2
x
|
44.1
x
|
17.3
x
|
11.3
x
|
8.22
x
|
6.09
x
|
EV / EBITDA
|
-27.3
x
|
-23.6
x
|
-45.7
x
|
-31.9
x
|
-
|
-98.7
x
|
93.4
x
|
25.7
x
|
EV / FCF
|
36.2
x
|
-28.2
x
|
-25.7
x
|
-22.8
x
|
-
|
-278
x
|
84.1
x
|
54.3
x
|
FCF Yield
|
2.76%
|
-3.55%
|
-3.9%
|
-4.39%
|
-
|
-0.36%
|
1.19%
|
1.84%
|
Price to Book
|
5.84
x
|
8.44
x
|
7.1
x
|
-
|
-
|
5.58
x
|
5.15
x
|
4.47
x
|
Nbr of stocks (in thousands)
|
42,762
|
47,108
|
51,668
|
55,324
|
59,079
|
59,387
|
-
|
-
|
Reference price
2 |
143.6
|
242.0
|
315.3
|
348.3
|
343.5
|
358.6
|
358.6
|
358.6
|
Announcement Date
|
2/27/20
|
3/4/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82.58
|
54.53
|
486.3
|
419.9
|
1,171
|
1,682
|
2,291
|
3,010
|
EBITDA
1 |
-176.4
|
-414.3
|
-310.4
|
-580.3
|
-
|
-192.5
|
201.6
|
713.2
|
EBIT
1 |
-178.6
|
-417.8
|
-314.4
|
-679.3
|
-392.3
|
-195.7
|
139.1
|
709.3
|
Operating Margin
|
-216.21%
|
-766.07%
|
-64.65%
|
-161.78%
|
-33.51%
|
-11.64%
|
6.07%
|
23.57%
|
Earnings before Tax (EBT)
1 |
-158.2
|
-526.3
|
-360.4
|
-687.7
|
-281
|
-109
|
225.6
|
851.4
|
Net income
1 |
-163
|
-528.9
|
-368.1
|
-669.1
|
-272.3
|
-136.8
|
218.9
|
732.5
|
Net margin
|
-197.33%
|
-969.9%
|
-75.69%
|
-159.36%
|
-23.26%
|
-8.13%
|
9.55%
|
24.34%
|
EPS
2 |
-4.220
|
-11.65
|
-7.203
|
-12.31
|
-4.763
|
-2.476
|
3.328
|
9.787
|
Free Cash Flow
1 |
133
|
-347.3
|
-552.7
|
-813.6
|
-
|
-68.32
|
223.7
|
337.6
|
FCF margin
|
161.02%
|
-636.85%
|
-113.66%
|
-193.76%
|
-
|
-4.06%
|
9.77%
|
11.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
110.96%
|
47.34%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
102.21%
|
46.1%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
3/4/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2021 Q3
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
31.28
|
6.131
|
40.42
|
-
|
29.8
|
84.08
|
145.5
|
171.7
|
309.9
|
207.8
|
253.8
|
461.4
|
320.3
|
385.7
|
699.3
|
374
|
399.5
|
-
|
435.8
|
476.6
|
-
|
503.2
|
-
|
-
|
EBITDA
1 |
-
|
-182.1
|
-197.7
|
-
|
-211.5
|
-170.3
|
-208
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-70.62
|
-72.62
|
-
|
-79.62
|
-53.09
|
-
|
-
|
-
|
-
|
EBIT
1 |
-94.09
|
-183.8
|
-208.2
|
-
|
-210.9
|
-172.3
|
-207.2
|
-107.9
|
-304.7
|
-93.84
|
-92.2
|
-185.9
|
-75.95
|
-127.9
|
-202.3
|
-56.55
|
-56.58
|
-
|
-41.68
|
-29.65
|
-
|
19.28
|
-
|
-
|
Operating Margin
|
-300.74%
|
-2,997.28%
|
-515.01%
|
-
|
-707.52%
|
-204.9%
|
-142.43%
|
-62.83%
|
-98.32%
|
-45.15%
|
-36.33%
|
-40.29%
|
-23.71%
|
-33.18%
|
-28.93%
|
-15.12%
|
-14.16%
|
-
|
-9.56%
|
-6.22%
|
-
|
3.83%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-113.4
|
-199.2
|
-220.8
|
-
|
-217.8
|
-214.2
|
-239.4
|
-38.89
|
-266.2
|
-68.9
|
-75.73
|
-144.5
|
-78.49
|
-56.47
|
-133.3
|
-37.24
|
-35.22
|
-
|
-17.86
|
-6.035
|
-
|
32.97
|
-
|
-
|
Net income
1 |
-117.8
|
-201.6
|
-214.4
|
-425
|
-215.1
|
-206
|
-233.5
|
-36.41
|
-258.1
|
-26.11
|
-85.22
|
-111.3
|
-68.47
|
-91.54
|
-158.6
|
-38.16
|
-37.96
|
-
|
-21.89
|
-12.01
|
-
|
38.18
|
-
|
-
|
Net margin
|
-376.68%
|
-3,288.02%
|
-530.42%
|
-
|
-721.69%
|
-245.06%
|
-160.45%
|
-21.2%
|
-83.28%
|
-12.57%
|
-33.58%
|
-24.12%
|
-21.38%
|
-23.73%
|
-22.68%
|
-10.2%
|
-9.5%
|
-
|
-5.02%
|
-2.52%
|
-
|
7.59%
|
-
|
-
|
EPS
2 |
-
|
-3.797
|
-4.291
|
-
|
-
|
-3.760
|
-4.231
|
-0.6601
|
-
|
-0.4703
|
-1.526
|
-
|
-1.178
|
-1.551
|
-
|
-0.5995
|
-1.497
|
-
|
-1.690
|
-1.090
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
10/28/21
|
3/3/22
|
3/3/22
|
5/5/22
|
7/28/22
|
10/27/22
|
3/2/23
|
3/2/23
|
5/4/23
|
7/27/23
|
7/27/23
|
10/31/23
|
2/29/24
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,329
|
1,619
|
2,105
|
754
|
-
|
2,306
|
2,472
|
2,955
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
133
|
-347
|
-553
|
-814
|
-
|
-68.3
|
224
|
338
|
ROE (net income / shareholders' equity)
|
-20.5%
|
-43.8%
|
-19.4%
|
-26.5%
|
-
|
-4.84%
|
3.83%
|
13.5%
|
ROA (Net income/ Total Assets)
|
-16.2%
|
-32.1%
|
-15.9%
|
-23.7%
|
-
|
-3.08%
|
4.47%
|
12.2%
|
Assets
1 |
1,006
|
1,646
|
2,312
|
2,822
|
-
|
4,439
|
4,898
|
6,001
|
Book Value Per Share
2 |
24.60
|
28.70
|
44.40
|
-
|
-
|
64.30
|
69.70
|
80.30
|
Cash Flow per Share
2 |
-
|
-
|
-10.80
|
-
|
-
|
1.030
|
3.840
|
11.60
|
Capex
1 |
1.6
|
0.95
|
3.28
|
0.79
|
-
|
6.97
|
9
|
14.3
|
Capex / Sales
|
1.94%
|
1.74%
|
0.67%
|
0.19%
|
-
|
0.41%
|
0.39%
|
0.47%
|
Announcement Date
|
2/27/20
|
3/4/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
358.6
EUR Average target price
439.3
EUR Spread / Average Target +22.51% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.40% | 22.94B | | -1.43% | 104B | | +8.96% | 105B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B | | -24.53% | 8.26B |
Bio Therapeutic Drugs
|